C-reactive protein in heart failure: prognostic value and the effect of valsartan. - Wikidata - awgldk - TriplyDB

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

http://www.wikidata.org/entity/Q46676009

about

Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective Effect of Cardiac Resynchronization Therapy on Inflammation in Congestive Heart Failure: A Review The fibrosis-cell death axis in heart failure On cross-sectional associations of leukocyte telomere length with cardiac systolic, diastolic and vascular function: the Asklepios study Pathophysiology of Heart Failure.Detection of the inflammation biomarker C-reactive protein in serum samples: towards an optimal biosensor formula.Reduced fractional shortening of right ventricular outflow tract is associated with adverse outcomes in patients with left ventricular dysfunction.Lipids, statins, and clinical outcomes in heart failure: rethinking the data.Rapid and Low-Cost CRP Measurement by Integrating a Paper-Based Microfluidic Immunoassay with Smartphone (CRP-Chip)Serum albumin level and hospital mortality in acute non-ischemic heart failure.The link of unintentional weight loss to cardiac event-free survival in patients with heart failure Lycopene dietary intervention: a pilot study in patients with heart failure Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic heart failure Low health-related quality of life is a predictor of major adverse cardiovascular events in patients with chronic nonischemic heart failure.Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction.High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study.Prognostic value of 6-minute walk test in stable outpatients with heart failure Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death Toxicological effect of TiO2 nanoparticle-induced myocarditis in mice.High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis Ambient temperature and biomarkers of heart failure: a repeated measures analysis.Reduction of C-reactive protein and the use of anti-hypertensives.Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.Inflammatory biomarkers in heart failure.Neutrophil-to-lymphocyte ratio predicts response to cardiac resynchronization therapy.Atorvastatin and statins in the treatment of heart failure.Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide Comparative value of simple inflammatory markers in the prediction of left ventricular systolic dysfunction in postacute coronary syndrome patients.Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury.Aldosterone Receptor Antagonism Reduces Urinary C-Reactive Protein Excretion in Angiotensin II-Infused, Hypertensive Rats.To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers.Prognostic value of biomarkers in heart failure: application of novel methods in the community.Post-exercise heart rate recovery independently predicts mortality risk in patients with chronic heart failure.

P2860

Q24594814-57EEB0FD-731C-49C1-A0E4-8BC82E071A96 Q27023183-08DB97CC-865E-45F3-837A-F4C2BEA01B8B Q28076570-F8F3F062-04FB-4C48-8118-720FB71A2A9F Q28542710-71220522-0C0D-496E-B811-39E0DE13F036 Q30315815-C40BDF11-94EC-40D1-8694-73E8E3999FCE Q30420948-5A0A1E1C-AB56-41CB-9AC8-1DDA9085E8DC Q30453514-FDB98B98-18B2-4CED-991A-267C96304BD6 Q30752824-8D552E52-1B80-429A-A266-9BD0FF58BF6C Q33453707-65455E42-3617-4761-A4F3-C8096404BC62 Q33577460-DD90C232-FAA0-4A20-9A9E-6185A9439A65 Q34036472-D9E1F9C5-CF0C-4C1A-A00D-24CED59CB10F Q34207466-15A2DC79-988B-4FD0-B39E-894934631123 Q34684331-5397D1F0-8269-45A8-844C-F0674DA5B48D Q34748917-49232812-F891-41DA-A901-0DB96015C036 Q34821528-BA23FCC6-552F-4A88-9ED8-058120FE9232 Q35026270-0BA372F2-3B5E-44D5-B8EB-A71985105A90 Q35065597-4643138F-6CAA-492E-852E-CBB9BDE2960B Q35234274-B9D06CAE-9C20-4519-B1AC-9A8634B8943A Q35562745-436742BD-9476-4400-AA50-25E83549615E Q35671382-61629168-1746-488C-A5D0-AD783FE6988C Q35705092-0AD4D508-CF18-45CA-9335-B125F8881575 Q35846621-11942EC2-3BDE-42B6-9AFE-77D0E9712A6D Q35899984-05D661BC-AB9D-4647-8D09-E4DB69AC2372 Q35946850-B1B50A94-F9A8-4F86-BC05-6842FC5B0D05 Q36158293-B990CBD9-5A40-4A72-9133-75FB48F74325 Q36229049-C2FF1882-7ADC-46D3-BD7B-673B39E6137F Q36596821-673470BE-95AD-4E2B-83DC-352E5E3B917E Q36649671-0C48942A-7924-4035-A96F-BBCAE5BD46BA Q36684755-1D28654E-2B36-4F56-9BEA-B31885E0732E Q36873806-5EBA0417-799A-4E33-969B-94FF389238B8 Q37000767-1931032E-43D9-4B5E-A278-FD0F3BD3BE69 Q37096739-E4EFB85A-BBE4-4A1C-8400-3E6CFACEF3F5 Q37102996-F05BD9CC-A487-4641-973D-39B0F6F9FF56 Q37202126-2C43748F-CE28-4C39-8119-83A72A2CAACD Q37210477-81C77224-E045-41D3-8ABC-79B08A8DB3FB Q37235292-AB0E497C-422F-444E-ACCC-5CDFD84B840F Q37340088-6D39E6F7-DF89-439F-82CB-5E5244C6F292 Q37359748-65C23968-AA24-4E3A-AF8C-93246F8CBD2E Q37413803-1CABAC55-2EE5-4209-803D-4D3522D116EB Q37452388-5B829EDD-C2F6-4DE3-9F4F-064280F82B60

P2860

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

http://www.wikidata.org/entity/Q46676009

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

@en

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

@nl

type

label

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

@en

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

@nl

prefLabel

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

@en

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

@nl

P1433

Q46676009-B145D44B-5B3E-4640-82B2-53C5D63D5C83

P1476

Q46676009-3EF13546-D4B4-44C4-A630-D618E95F61A0

P2093

Q46676009-0B98AED6-2611-4649-964A-2075AEF576F5

Q46676009-427F403B-0ECF-4F11-86A4-5B5402A46CE9

Q46676009-599391D9-BB0A-409A-9DF6-B7FAB6B76D71

Q46676009-767DC86E-3DE6-4D39-8564-FB57839D744B

Q46676009-8AEE1CD3-89D1-4FEE-98E0-C45E6D5947E9

Q46676009-93282308-E969-4247-9E89-9498DC55EA61

Q46676009-93A9289B-1905-4249-A691-971C796836DA

Q46676009-9AB7D591-1855-4B40-8A1B-BA253E51F52A

Q46676009-B1C4478A-E5D1-42FA-8971-283A5D28BFC8

Q46676009-BA363B01-EEFA-4551-BD79-4B261D74977E

P304

Q46676009-98C6C05B-C944-48F5-AB47-EE3A5FBACBE5

P31

Q46676009-CA02CD30-E2FC-4238-81EC-9B950D3E338E

P356

Q46676009-E4B3243F-5FDF-44C2-88FE-2BCF39011B14

P407

Q46676009-28E54B3F-955D-4819-8E4F-458C5CD73855

P433

Q46676009-7351FBE9-C33F-4341-9EC1-264097E1F2FB

P478

Q46676009-EEA2508A-C575-4691-80DD-1D76DE01CF54

P577

Q46676009-C88A45B3-9302-4537-8ACB-3141C589F5D3

P698

Q46676009-9EE2CCF2-C936-4249-8232-815B194CFECA

P921

Q46676009-8E19DEDE-D7AB-4D7E-9792-67912E33D408

P356

CIRCULATIONAHA.104.508465

P1433

P1476

C-reactive protein in heart failure: prognostic value and the effect of valsartan.

@en

P2093

Allen Hester

http://www.w3.org/2001/XMLSchema#string

Inder S Anand

http://www.w3.org/2001/XMLSchema#string

Jay N Cohn

http://www.w3.org/2001/XMLSchema#string

Michael A Kuskowski

http://www.w3.org/2001/XMLSchema#string

Paolo Mocarelli

http://www.w3.org/2001/XMLSchema#string

Robert Glazer

http://www.w3.org/2001/XMLSchema#string

Roberto Latini

http://www.w3.org/2001/XMLSchema#string

Serge Masson

http://www.w3.org/2001/XMLSchema#string

Stefano Signorini

http://www.w3.org/2001/XMLSchema#string

Thomas Rector

http://www.w3.org/2001/XMLSchema#string

P304

1428-1434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.104.508465

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16129801

http://www.w3.org/2001/XMLSchema#string

P921